QuantLogix ← DXCM scorecard
📅 DXCM Earnings Preview
DexCom, Inc. Common Stock
Next report (est.)
10/29/2026
Countdown
1 days
EPS growth YoY
+42.2%
Revenue growth YoY
+13.1%
Options-implied earnings move
±8.6%
The at-the-money straddle prices a move to roughly $85.79 or $72.19 from $78.99 by 10/30/2026.
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
07/30/2026 ±3.1% -0.8% over-priced
04/30/2026 ±4.0% +3.5% over-priced
02/12/2026 ±3.1% -4.5% under-priced
10/30/2025 ±3.0% +0.0% over-priced
07/30/2025 ±1.6% -0.3% over-priced
05/01/2025 ±3.1% -1.6% over-priced
02/18/2025 ±3.3% +1.6% over-priced
10/24/2024 ±2.4% +3.3% under-priced
Across these reports, options implied an average ±2.9% move vs an actual average of 1.9% — the stock stayed inside the implied band 75% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $0.64 $1.3B $249M
Q1 FY2026 $0.51 $1.2B $200M
Q4 FY2025 — $1.3B $267M
Q3 FY2025 $0.70 $1.2B $284M
Analyst posture
Buy / Strong Buy
30
Hold
5
Sell
0
Stable: -1 net change 30d
Live 5-factor engine read: Buy · 64/100 Full scorecard →
Get alerted before every DXCM report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on DXCM before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

DexCom, Inc. Common Stock (DXCM) reports in 1 day, with the next report estimated for 10/29/2026. Across the last 8 reports, options priced an average ±2.9% earnings move while the stock actually moved 1.9% on average — the market has systematically over-priced DXCM's earnings risk. Fundamentals into the print: EPS up 42.2% year-over-year, revenue up 13.1%. QuantLogix's live 5-factor engine currently reads DXCM as a buy at 64/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →